biOasis Technologies Inc
XTSX:BTI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
F
|
Footway Group AB
STO:FOOT PREF
|
SE |
biOasis Technologies Inc
Accounts Payable
biOasis Technologies Inc
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
biOasis Technologies Inc
XTSX:BTI
|
Accounts Payable
CA$1.9m
|
CAGR 3-Years
1%
|
CAGR 5-Years
33%
|
CAGR 10-Years
29%
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Accounts Payable
CA$1.7m
|
CAGR 3-Years
42%
|
CAGR 5-Years
65%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Accounts Payable
$3.3m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
5%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Accounts Payable
$3.9m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
5%
|
CAGR 10-Years
12%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Accounts Payable
CA$5.5m
|
CAGR 3-Years
12%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Accounts Payable
$6.7m
|
CAGR 3-Years
110%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
biOasis Technologies Inc
Glance View
biOasis Technologies, Inc. operates as a biopharmaceutical company. The company is headquartered in Richmond British Columbia, British Columbia. The company went IPO on 2007-07-24. The firm is engaged in the development of the xB3 platform, a technology for the delivery of therapeutics across the blood brain barrier (BBB) and the treatment of central nervous system (CNS) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. xB3 is based on a human transport protein found circulating at low levels in the blood. The xB3 platform has an efficacy in its ability to shuttle molecules across the blood-brain barrier and reach its targets within the brain through a process called receptor-mediated transcytosis. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.
See Also
What is biOasis Technologies Inc's Accounts Payable?
Accounts Payable
1.9m
CAD
Based on the financial report for Nov 30, 2022, biOasis Technologies Inc's Accounts Payable amounts to 1.9m CAD.
What is biOasis Technologies Inc's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
29%
Over the last year, the Accounts Payable growth was 52%. The average annual Accounts Payable growth rates for biOasis Technologies Inc have been 1% over the past three years , 33% over the past five years , and 29% over the past ten years .
